Fenofibrate modified-release pellets with lag phase and high oral bioavailability

PURPOSE: Fenofibrate and statin combination therapy is highly recommended by the current clinical guidelines for treatment of mixed dyslipidemia. In this study, an innovative delayed-release preparation of fenofibrate was designed to reduce the risk of muscle toxicity, caused by simultaneous adminis...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Fang, Zheng, Xin, Bao, YongChu, Chen, Ting, Zeng, Jia, Xu, XiaoLi, Yan, Chao, Feng, LingLin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307495/
https://www.ncbi.nlm.nih.gov/pubmed/30613135
http://dx.doi.org/10.2147/DDDT.S179266

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307495/
https://www.ncbi.nlm.nih.gov/pubmed/30613135
http://dx.doi.org/10.2147/DDDT.S179266

Ejemplares similares